|
|
|
|
|
|
|
|
open access
Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials
Literature search and inclusion criteria
CONCLUSIONSThe literature search focused on randomized controlled trials published from database inception to May 2016. Studies comparing bevacizumab plus chemotherapy with chemotherapy alone were eligible for inclusion. We searched the PubMed, EMBASE, Web of Science and Central (Cochrane clinical trials database) databases, and we also searched clinicaltrial.gov. We used the search terms “bevacizumab”, “Avastin”, “chemotherapy”, and “ovarian cancer” in various combinations. In addition, only phase III randomized trials were restricted in the search strategy. The language of an article published was not restricted.
This
updated meta-analysis indicates that bevacizumab combined with
chemotherapy significantly improved PFS and OS in both patients with
high-risk of progression and patients with recurrent OC, with an
increased incidence of common adverse events. However, no statistically
significant survival benefit was identified in the front-line settings.
ORR is improved in overall population by the addition of bevacizumab.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.